2.55
-0.3927(-13.36%)
Currency In USD
| Previous Close | 2.94 |
| Open | 2.76 |
| Day High | 2.78 |
| Day Low | 2.42 |
| 52-Week High | 3.94 |
| 52-Week Low | 0.69 |
| Volume | 8.6M |
| Average Volume | 6.62M |
| Market Cap | 513.4M |
| PE | -4.72 |
| EPS | -0.54 |
| Moving Average 50 Days | 2.69 |
| Moving Average 200 Days | 1.72 |
| Change | -0.39 |
If you invested $1000 in Esperion Therapeutics, Inc. (ESPR) 10 years ago, it would be worth $91.73 as of November 06, 2025 at a share price of $2.547. Whereas If you bought $1000 worth of Esperion Therapeutics, Inc. (ESPR) shares 5 years ago, it would be worth $100.88 as of November 06, 2025 at a share price of $2.547.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of John Harlow as the C
Esperion to Participate in Jefferies Global Healthcare Conference - London
GlobeNewswire Inc.
Nov 03, 2025 1:00 PM GMT
ANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Jefferies Global Healthcare Conference – London on November 18, 2025, at 8:00 a.m. GMT (3:00 a.m. ET). The live webcast
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
– Leading Cardiovascular Physician Experts to Explore Real-World Challenges and Impact on Patient Outcomes – ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL)